William P. Forbes - 30 Jan 2026 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)

Role
EVP, Chief Development Officer
Signature
/s/ Kathryn Lester Attorney-in-fact for William P. Forbes
Issuer symbol
HRTX
Transactions as of
30 Jan 2026
Net transactions value
$0
Form type
4
Filing time
03 Feb 2026, 10:00:05 UTC
Previous filing
20 Jan 2026
Next filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Forbes William P EVP, Chief Development Officer 100 REGENCY FOREST DRIVE, SUITE 300, CARY /s/ Kathryn Lester Attorney-in-fact for William P. Forbes 03 Feb 2026 0001314760

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRTX Restricted Stock Units Award $0 +188,315 $0.000000 188,315 30 Jan 2026 Common Stock 188,315 Direct F1, F2
transaction HRTX Performance Stock Units Award $0 +188,314 $0.000000 188,314 30 Jan 2026 Common Stock 188,314 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 188,315 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein.
F3 Performance stock units ("PSUs") convert into common stock on a one-for-one basis.
F4 On January 30, 2026, the Reporting Person was granted 188,314 PSUs which vest upon the following time-based vesting schedule: the PSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant, subject to satisfaction of the milestone-based vesting condition: the applicable percentage of the PSUs vesting based on a net product sales revenue target for the fiscal year ending December 31, 2026 as reported in the Issuer's Form 10-K. The full amount of the PSUs granted to the Reporting Person is reflected herein.